These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3493624)

  • 21. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): one designer drug and serendipity.
    Weingarten HL
    J Forensic Sci; 1988 Mar; 33(2):588-95. PubMed ID: 3259617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MPTP administration increases plasma levels of acute phase proteins in non-human primates (Macaca fascicularis).
    De Pablos V; Barcia C; Martínez S; Gomez A; Ros-Bernal F; Zamarro-Parra J; Soria-Torrecillas JJ; Hernández J; Ceron JJ; Herrero MT
    Neurosci Lett; 2009 Sep; 463(1):37-9. PubMed ID: 19638294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The MPTP story: an introduction.
    Marsden CD; Sandler M
    J Neural Transm Suppl; 1986; 20():1-3. PubMed ID: 3091759
    [No Abstract]   [Full Text] [Related]  

  • 24. Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia.
    Silverdale MA; Crossman AR; Brotchie JM
    Exp Neurol; 2002 Mar; 174(1):21-8. PubMed ID: 11869030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of increasing regimens of levodopa on chronic MPTP-induced parkinsonism in monkey; mechanographic and electromyographic data.
    Doudet D; Gross C; Lebrun-Grandie P; Bioulac B
    Electromyogr Clin Neurophysiol; 1986 Dec; 26(8):711-27. PubMed ID: 3493894
    [No Abstract]   [Full Text] [Related]  

  • 26. Glutamic acid decarboxylase mRNA expression in medial and lateral pallidal neurons in the MPTP-treated monkey and patients with Parkinson's disease.
    Herrero MT; Levy R; Ruberg M; Javoy-Agid F; Luquin MR; Agid Y; Hirsch EC; Obeso JA
    Adv Neurol; 1996; 69():209-16. PubMed ID: 8615130
    [No Abstract]   [Full Text] [Related]  

  • 27. Pathology of MPTP in the marmoset.
    Gibb WR; Lees AJ; Wells FR; Barnard RO; Jenner P; Marsden CD
    Adv Neurol; 1987; 45():187-90. PubMed ID: 3103386
    [No Abstract]   [Full Text] [Related]  

  • 28. Development of new pharmacological approaches in Parkinson's disease.
    Carlsson A
    Adv Neurol; 1987; 45():513-8. PubMed ID: 3493631
    [No Abstract]   [Full Text] [Related]  

  • 29. Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger.
    Blanchet PJ; Konitsiotis S; Hyland K; Arnold LA; Pettigrew KD; Chase TN
    Exp Neurol; 1998 Oct; 153(2):214-22. PubMed ID: 9784281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mechanism of induction of parkinsonism by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a dopaminergic neurotoxin].
    Hirata Y; Nagatsu T
    Tanpakushitsu Kakusan Koso; 1986 Apr; 31(5):398-409. PubMed ID: 3520683
    [No Abstract]   [Full Text] [Related]  

  • 31. Symptoms and behavioral features induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in an old Java monkey [Macaca cynomolgus fascicularis (Raffles)].
    Degryse AD; Colpaert FC
    Brain Res Bull; 1986 May; 16(5):561-71. PubMed ID: 3488798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on ultrastructure of nigral neuromelanin in Macaca fascicularis.
    Levi AC; DeMattei M; Ravazzani R; Corvetti G; Golden GT; Fariello RG
    Neurosci Lett; 1989 Jan; 96(3):271-6. PubMed ID: 2785665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys.
    Cohen G; Pasik P; Cohen B; Leist A; Mytilineou C; Yahr MD
    Eur J Pharmacol; 1984 Oct; 106(1):209-10. PubMed ID: 6442232
    [No Abstract]   [Full Text] [Related]  

  • 34. Changes in the rates of the tricarboxylic acid (TCA) cycle and glutamine synthesis in the monkey brain with hemiparkinsonism induced by intracarotid infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): studies by non-invasive 13C-magnetic resonance spectroscopy.
    Kanamatsu T; Otsuki T; Tokuno H; Nambu A; Takada M; Okamoto K; Watanabe H; Umeda M; Tsukada Y
    Brain Res; 2007 Nov; 1181():142-8. PubMed ID: 17919469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parkinson's disease in 1984: an update.
    Lang AE; Blair RD
    Can Med Assoc J; 1984 Nov; 131(9):1031-7. PubMed ID: 6388779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A simple quantitative bradykinesia test in MPTP-treated mice.
    Ogawa N; Hirose Y; Ohara S; Ono T; Watanabe Y
    Res Commun Chem Pathol Pharmacol; 1985 Dec; 50(3):435-41. PubMed ID: 3878557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early parkinsonism.
    Calne DB; Stoessl AJ
    Clin Neuropharmacol; 1986; 9 Suppl 2():S3-8. PubMed ID: 3297316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coenzyme Q, peroxidation and cytochrome oxidase features after parkinson's-like disease by MPTP toxicity in intra-synaptic and non-synaptic mitochondria from Macaca fascicularis cerebral cortex and hippocampus: action of dihydroergocriptine.
    Battino M; Littarru GP; Gorini A; Villa RF
    Neurochem Res; 1996 Dec; 21(12):1505-14. PubMed ID: 8953566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MPTP: current concepts and controversies.
    Langston JW; Irwin I
    Clin Neuropharmacol; 1986; 9(6):485-507. PubMed ID: 3542203
    [No Abstract]   [Full Text] [Related]  

  • 40. Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model.
    Kim NK; Choi BH; Huang X; Snyder BJ; Bukhari S; Kong TH; Park H; Park HC; Park SR; Ha Y
    Eur J Neurosci; 2009 Mar; 29(5):891-900. PubMed ID: 19245369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.